BMRN BioMarin Pharmaceutical Inc. - Common Stock
NASDAQ · Biotechnology · Wyświetl na SEC EDGAR ↗ zamknij Paź 2, 2026 10-K/10-Q Sie 6, 2026BMRN Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
BMRN Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
Granularność słupków dostosowuje się do wybranego okresu — najedź kursorem na wykres, aby zobaczyć otwarcia/maksima/minima/zamknięcia dla danego słupka.
O BioMarin Pharmaceutical Inc. - Common Stock Przegląd firmy z Wikipedii
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I (MPS I), by manufacturing laronidase (Aldurazyme, commercialized by Genzyme Corporation). BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials.
History
BioMarin was founded in 1997 by Christopher Starr Ph.D. and Grant W. Denison Jr. with an investment of a $1.5 million from Glyko Biomedical and went public in 1999. Seed investors were amongst others MPM Bioventures, Grosvenor Fund and Florian Schönharting.
Business development
In 2002, BioMarin acquired Glyko Biomedical.
In 2009, BioMarin acquired Huxley Pharmaceuticals, Inc. (Huxley), which had rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate. In 2010, BioMarin was granted marketing approval by the European Commission for 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate for the treatment of the rare autoimmune disease Lambert–Eaton myasthenic syndrome (LEMS). BioMarin launched the product under the name Firdapse.
In 2010, BioMarin acquired LEAD Therapeutics, Inc. (LEAD), a small private drug discovery and early stage development company with key compound LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor studied for the treatment of patients with rare, genetically defined cancers. This acquisition was followed by the purchase of ZyStor Therapeutics, Inc. (ZyStor), a privately held biotechnology company developing ERTs for the treatment of lysosomal storage disorders and its lead product candidate, ZC-701, a fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for Pompe disease. At its R&D day in October 2010, BioMarin also announced a new program for a peptide therapeutic, vosoritide (BMN-111), for the treatment of achondroplasia.
In 2012, BioMarin acquired Zacharon Pharmaceuticals, a private biotechnology company based in San Diego focused on developing small molecules targeting pathways of glycan metabolism.
In 2014, BioMarin acquired a histone deacetylase inhibitor chemical library from Repligen for $2 million with the intention of advancing work toward therapies for Friedreich's ataxia and other neurological disorders.
In November 2014, the company agreed to the acquisition of Prosensa for up to $840 million; however, the range of treatments for Duchenne muscular dystrophy failed to attain FDA approval, and development ceased in May 2016.
In October 2019 it was revealed that the group will open an office in Dublin to support further growth through Europe, the Middle East and Asia.
In December 2025, BioMarin agreed to acquire Amicus Therapeutics for $4.8 billion.
Acquisition history
The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):
Products
As of 2022, BioMarin has six products on the market, each of which is an orphan drug.
Tetrahydrobiopterin (branded as Kuvan) (sapropterin dihydrochloride), a small molecule drug for phenylketonuria, introduced in 2007 as the first medication-based intervention to treat phenylketonuria
Arylsulfatase B (branded as Naglazyme) (galsulfase), a recombinant protein therapeutic for Maroteaux–Lamy syndrome (also called mucopolysaccharidosis type VI)
Iduronidase (branded as Aldurazyme), a recombinant protein therapeutic for mucopolysaccharidosis I
Amifampridine (branded as Firdapse), a small molecule drug for Lambert–Eaton myasthenic syndrome (as of 2013 approved in the EU only)
Elosulfase alfa (branded as Vimizim), is the only enzyme replacement therapy to address the cause of Morquio A Syndrome (MPS IVA), which affects an estimated 3,000 patients in the developed world. The disease occurs as a result of a deficiency of activity in an enzyme involved in glycosaminoglycan (GAG) metabolism.
Cerliponase alfa (branded as Brineura), is an enzyme replacement treatment for Batten disease, which is a form of neuronal ceroid lipofuscinosis. It was approved in 2017.
Valoctocogene roxaparvovec (branded as Roctavian) is an adeno-associated viral vector for treatment of hemophilia A that aims to transfer a working copy of the Factor VIII gene into patients who lack one. It was approved in the EU in August 2022.
Biomarin is working to develop several new drugs.
Controversies
In 2010, BioMarin became involved in controversy surrounding 3,4-diaminopyridine (3,4-DAP). BioMarin markets a phosphate salt of 3,4-DAP under the name Firdapse. In 2010, BioMarin was granted exclusive licensing rights to Firdapse for 10 years. As a result, the price of a prescribed National Health Service treatment course has increased from $1,987 for the unlicensed drug to $69,970 for Firdapse. The company states that prior to its licensing, there was no guaranteed quality control of the product and no way of formally monitoring for uncommon side effects through the regulatory process.
In 2013, BioMarin Pharmaceuticals was at the center of a high-profile debate regarding expanded access of cancer patients to experimental drugs. On the advice of her doctor, Andrea Sloan, a patient with advanced ovarian cancer, requested that the company provide her with access to BMN 673, an unapproved PARP inhibitor drug candidate that had exhibited promising activity in a small Phase 1 clinical trial. The company declined, citing safety concerns. Ms. Sloan eventually received a similar drug candidate from a different company.
In 2015, there was another controversy over expanded access, concerning the supply of a drug on clinical trial to a German child who was suffering from a brain disorder but who was not part of the trial.
In April 2019, the BBC reported that patients who took part in a trial treatment for the drug Kuvan (sapropterin hydrochloride) were later denied access to it. The company was criticised by the NHS and Stephen Hammond MP for patient profiteering. The company commented the following in response: "BioMarin is disappointed that the NHS England has not recognised the value of treating PKU patients with Kuvan, despite more than a decade of positive patient outcomes across 26 countries in Europe, Russia and Turkey"
In June 2019, a Belgian court ordered BioMarin to continue supplying Vimizim to a young girl suffering from Morquio syndrome free of charge. BioMarin stopped providing free Vimizim at the beginning of the year after negotiations with Belgian health authorities regarding reimbursement of the product repeatedly failed. This caused the parents to start legal proceedings to force the company to keep providing the medicine free of charge. BioMarin was ordered in a preliminary injunction to keep doing so until a definitive judgment would be rendered, or until the medicine would be available on the Belgian market at a reasonable price.
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
| Wskaźnik | Trend 5-letni | BMRN | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| P/E (TTM) | 146.6średnia z 5 lat ≈11.8 | ≈11.8 | · | · | |
| P/S (TTM) | 3.2średnia z 5 lat ≈6.7 | ≈6.7 | 20.4 | Niedowartościowany | |
| P/B (MRQ) | 1.8średnia z 5 lat ≈3.2 | ≈3.2 | 11.3 | Niedowartościowany | |
| Cena / FCF (TTM) | 15.0średnia z 5 lat ≈152.1 | ≈152.1 | · | · | |
| Cena / Przepływy pieniężne (TTM) | 12.9średnia z 5 lat ≈62.6 | ≈62.6 | · | · | |
| Cena / Wartość księgowa materialna (MRQ) | 7.7średnia z 5 lat ≈3.5 | ≈3.5 | · | · |
Mediana porównawcza jest obliczana na znormalizowanej podstawie dla każdej metryki i może nie zawsze odpowiadać podstawie TTM/MRQ pokazanej dla tej akcji.
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
| Wskaźnik | Trend 5-letni | BMRN | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Marża Operacyjna (TTM) | 4.4%średnia z 5 lat ≈7.8% | ≈7.8% | -30.6% | Najwyższa półka | |
| Marża EBITDA (TTM) | 8.9%średnia z 5 lat ≈12.0% | ≈12.0% | -30.6% | Najwyższa półka | |
| Marża przed opodatkowaniem (TTM) | 4.4%średnia z 5 lat ≈9.0% | ≈9.0% | -29.3% | Najwyższa półka | |
| Marża Zysku Netto (TTM) | 2.1%średnia z 5 lat ≈7.2% | ≈7.2% | -29.6% | Najwyższa półka | |
| ROA (TTM) | 0.76%średnia z 5 lat ≈2.9% | ≈2.9% | -22.9% | Najwyższa półka | |
| ROE (TTM) | 1.2%średnia z 5 lat ≈3.7% | ≈3.7% | 18.1% | Słaby | |
| ROIC | 4.9%średnia z 5 lat ≈3.2% | ≈3.2% | 14.3% | Słaby |
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
| Wskaźnik | Trend 5-letni | BMRN | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Dług / Kapitał Własny (MRQ) | 0.7 | · | 0.3 | Wysokie zadłużenie | |
| Wskaźnik bieżący (MRQ) | 2.4średnia z 5 lat ≈4.4 | ≈4.4 | 3.2 | Niska płynność | |
| Quick Ratio (Wskaźnik Szybkości) | 2.9średnia z 5 lat ≈2.1 | ≈2.1 | 1.8 | Niska płynność | |
| Dług długoterminowy / Kapitał własny (MRQ) | 0.6 | · | 0.6 | Zgodnie z |
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
| Wskaźnik | Trend 5-letni | BMRN | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Revenue YoY (Przychody R/R) | 12.9%średnia z 5 lat ≈11.8% | ≈11.8% | · | · | |
| Revenue CAGR 3Y (Przychody CAGR 3L) | 15.4%średnia z 5 lat ≈13.4% | ≈13.4% | · | · | |
| Revenue CAGR 5Y (Przychody CAGR 5L) | 11.6% | · | · | · | |
| EPS YoY | -18.6%średnia z 5 lat ≈50.5% | ≈50.5% | · | · | |
| Net Income YoY (Zysk Netto R/R) | -18.3%średnia z 5 lat ≈51.6% | ≈51.6% | · | · | |
| EPS CAGR 3Y (CAGR z EPS 3 lata) | 33.9% | · | · | · | |
| EPS CAGR 5Y (CAGR z EPS 5 lat) | -16.7% | · | · | · | |
| Net Income CAGR 3Y (CAGR z zysku netto 3 lata) | 35.1% | · | · | · | |
| Net Income CAGR 5Y (CAGR z zysku netto 5 lat) | -16.4% | · | · | · |
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
| Wskaźnik | Trend 5-letni | BMRN | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Asset Turnover (Rotacja aktywów) | 0.4średnia z 5 lat ≈0.4 | ≈0.4 | 0.4 | Zgodnie z | |
| Inventory Turnover (Rotacja zapasów) | 0.6średnia z 5 lat ≈0.6 | ≈0.6 | 1.0 | Poniżej średniej | |
| Receivables Turnover (Rotacja należności) | 4.1średnia z 5 lat ≈4.5 | ≈4.5 | 5.1 | Słaby | |
| Revenue / Employee (Przychody / pracownika) | ≈$1.0M | · | · | · |
wartość · ≈ średnia z 5 lat · mediana branżowa · werdykt względem mediany
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
| Okres | Raport | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|---|
| 30 czerwca 2026 | Sie 3, 2026 | $0.73 | $0.70 | 4.0% |
| 31 marca 2026 | $0.54 | $0.77 | -29.5% | |
| 31 grudnia 2025 | $-0.24 | $0.64 | -137.7% | |
| 30 września 2025 | $-0.16 | $0.38 | -142.2% | |
| 30 czerwca 2025 | $1.23 | $0.85 | 44.4% | |
| 31 marca 2025 | $0.95 | $0.72 | 31.5% |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B | $1.86B | $1.70B | $1.49B | $1.31B | $1.12B | $890M | $749M | |
| Cost of Revenue | $717M | $580M | $532M | $503M | $471M | $524M | $359M | $315M | $242M | $210M | $152M | $122M | |
| R&D Expense | $922M | $747M | $747M | $650M | $629M | $628M | $715M | $696M | $611M | $662M | $635M | $462M | |
| SG&A Expense | $1.15B | $1.01B | $892M | $823M | $759M | $738M | $681M | $604M | $554M | $477M | $402M | $302M | |
| Operating Expenses | $2.81B | $2.37B | $2.23B | $1.94B | $1.93B | $1.90B | $1.80B | $1.61B | $1.33B | $1.92B | $1.00B | $842M | |
| Operating Income | $409M | $484M | $186M | $161M | $-82M | $-43M | $-100M | $-124M | $-15M | $-803M | $-111M | $-93M | |
| Interest Expense | · | · | $17M | $16M | $15M | $29M | $23M | $44M | $43M | $39M | $38M | $37M | |
| Interest Income | $75M | $75M | $58M | $18M | $10M | $17M | $23M | $23M | $15M | $7M | $5M | $6M | |
| Pretax Income | $482M | $542M | $189M | $150M | $-75M | $-49M | $-95M | $-143M | $-36M | $-831M | $-155M | $-125M | |
| Income Tax | $134M | $115M | $21M | $8M | $-11M | $-903M | $-71M | $-65M | $81M | $-201M | $17M | $9M | |
| Net Income | $349M | $427M | $168M | $142M | $-64M | $854M | $-24M | $-77M | $-117M | $-630M | $-172M | $-134M | |
| EPS (Basic) | $1.82 | $2.25 | $0.89 | $0.76 | $-0.35 | $4.72 | $-0.13 | $-0.44 | $-0.67 | $-3.80 | $-1.07 | $-0.92 | |
| EPS (Diluted) | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 | $4.50 | $-0.13 | $-0.44 | $-0.67 | $-3.81 | $-1.07 | $-0.92 | |
| Shares (Basic) | 191,787,000 | 190,027,000 | 187,834,000 | 185,266,000 | 182,852,000 | 180,804,000 | 179,039,000 | 177,061,000 | 174,427,000 | 165,985,000 | 160,025,000 | 146,349,000 | |
| Shares (Diluted) | 197,394,000 | 196,708,000 | 191,595,000 | 188,963,000 | 182,852,000 | 191,678,000 | 179,039,000 | 177,268,000 | 174,427,000 | 166,219,000 | 160,025,000 | 146,349,000 | |
| EBITDA | $489M | $581M | $262M | $252M | $26M | $68M | $5M | $-28M | $73M | $-707M | $-64M | $-93M |
Bilans
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.31B | $943M | $755M | $725M | $587M | $649M | $437M | $494M | $598M | $408M | $397M | $875M | |
| Short-term Investments | · | · | · | · | · | · | · | · | $798M | $381M | $196M | $70M | |
| Receivables | $908M | $661M | $634M | $461M | $373M | $448M | $377M | $343M | $261M | $215M | $165M | $144M | |
| Inventory | $1.30B | $1.23B | $1.11B | $894M | $777M | $699M | $680M | $531M | $476M | $355M | $272M | $199M | |
| Prepaid Expense | · | · | · | · | · | · | · | · | · | · | $28M | $35M | |
| Other Current Assets | $186M | $202M | $141M | $105M | $110M | $130M | $131M | $98M | $74M | $62M | $60M | $109M | |
| Current Assets | $3.95B | $3.23B | $2.96B | $2.75B | $2.27B | $2.34B | $1.94B | $2.06B | $2.21B | $1.42B | $1.09B | $1.40B | |
| PP&E (Net) | $953M | $1.04B | $1.07B | $1.07B | $1.04B | $1.03B | $1.01B | $949M | $897M | $799M | $704M | $524M | |
| PP&E (Gross) | $2.03B | $1.93B | $1.93B | $1.88B | $1.76B | $1.67B | $1.56B | $1.42B | $1.30B | $1.14B | $983M | $752M | |
| Accum. Depreciation | $1.07B | $892M | $867M | $802M | $721M | $636M | $549M | $473M | $407M | $343M | $279M | $229M | |
| Goodwill | $196M | $196M | $196M | $196M | $196M | $196M | $197M | $197M | $197M | $197M | $197M | $54M | |
| Intangibles | $214M | $255M | $295M | $339M | $389M | $417M | $457M | $492M | $518M | $554M | $684M | $157M | |
| Other Non-current Assets | $277M | $251M | $172M | $176M | $152M | $142M | $122M | $37M | $30M | $33M | $409M | $55M | |
| Total Assets | $7.59B | $6.99B | $6.84B | $6.38B | $6.00B | $5.85B | $4.69B | $4.43B | $4.63B | $4.02B | $3.73B | $2.48B | |
| Accounts Payable | $759M | $607M | $683M | $573M | $498M | $493M | $571M | $437M | $402M | $371M | $393M | $232M | |
| Accrued Liabilities | · | · | · | · | · | · | · | · | · | · | · | $98M | |
| Current Liabilities | $759M | $607M | $1.18B | $589M | $546M | $493M | $933M | $523M | $817M | $439M | $445M | $236M | |
| Capital Leases | $37M | $31M | $38M | $26M | $32M | $40M | $44M | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $0 | $144M | · | |
| Other Non-current Liabilities | $151M | $129M | $120M | $100M | $98M | $114M | $98M | $59M | $59M | $42M | $45M | $30M | |
| Total Liabilities | $1.51B | $1.33B | $1.89B | $1.77B | $1.74B | $1.74B | $1.57B | $1.46B | $1.82B | $1.26B | $1.33B | $947M | |
| Long-term Debt | $597M | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $192.0K | $191.0K | $189.0K | $186.0K | $184.0K | $182.0K | $180.0K | $178.0K | $176.0K | $173.0K | $162.0K | $149.0K | |
| Retained Earnings | $154M | $-195M | $-622M | $-789M | $-931M | $-862M | $-1.72B | $-1.69B | $-1.64B | $-1.52B | $-1.02B | $-850M | |
| AOCI | $-13M | $62M | $-29M | $-4M | $14M | $-16M | $20M | $5M | $-23M | $13M | $21M | $27M | |
| Stockholders' Equity | $6.09B | $5.66B | $4.95B | $4.60B | $4.27B | $4.10B | $3.12B | $2.97B | $2.81B | $2.77B | $2.40B | $1.53B | |
| Liabilities + Equity | $7.59B | $6.99B | $6.84B | $6.38B | $6.00B | $5.85B | $4.69B | $4.43B | $4.63B | $4.02B | $3.73B | $2.48B | |
| Shares Outstanding | 192,300,101 | 190,761,000 | 188,598,000 | 186,251,000 | 183,913,000 | 181,741,000 | 179,838,000 | 178,252,954 | 175,843,749 | 172,647,588 | 161,526,044 | 149,093,647 |
Przepływy pieniężne
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $80M | $96M | $104M | $102M | $108M | $105M | $105M | $96M | $88M | $97M | $47M | $46M | |
| Stock-based Comp | $181M | $202M | $207M | $196M | $197M | $190M | $160M | $149M | $140M | $135M | $112M | $86M | |
| Deferred Tax | $49M | $56M | $-45M | $-52M | $-16M | $-890M | $-83M | $-68M | $44M | $-228M | $-77M | $-26M | |
| Amort. of Intangibles | $19M | $43M | $62M | $67M | · | · | · | · | · | · | · | $10M | |
| Other Non-cash | $169M | $-208M | $-275M | $-212M | $79M | $-180M | $-110M | $-79M | $-164M | $399M | $-132M | · | |
| Operating Cash Flow | $828M | $573M | $159M | $176M | $305M | $85M | $48M | $20M | $-9M | $-228M | $-219M | $-70M | |
| CapEx | $103M | $85M | $97M | $121M | $96M | $114M | $145M | $145M | $199M | $148M | $228M | $117M | |
| Investing Cash Flow | $-414M | $136M | $-111M | $-20M | $-366M | $-54M | $-31M | $264M | $-305M | $-484M | · | · | |
| Stock Issued | · | · | · | · | · | · | · | $0 | $0 | $713M | $888M | $117M | |
| Stock Repurchased | · | · | · | $0 | $0 | $50M | $0 | $0 | · | · | · | · | |
| Net Stock Activity | · | · | · | $0 | $0 | $-50M | · | $0 | $0 | $713M | $888M | $117M | |
| Financing Cash Flow | $-42M | $-526M | $-19M | $-19M | $-48.0K | $181M | $-75M | $-388M | $507M | $727M | · | · | |
| Net Change in Cash | $369M | $188M | $31M | $137M | $-62M | $212M | $-57M | $-104M | $190M | $11M | $-478M | $307M | |
| Taxes Paid | $96M | · | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $725M | $487M | $63M | $55M | $209M | $-29M | $-97M | $-124M | $-208M | $-376M | $-449M | $-192M | |
| Levered FCF | · | · | $47M | $40M | $196M | $566M | $-103M | $-148M | $-347M | $-406M | $-492M | $-232M |
Rentowność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 12.7% | 17.0% | 6.5% | 7.1% | -4.5% | -2.0% | -5.9% | -8.3% | -1.1% | -71.9% | -12.4% | -12.4% | |
| Net Margin | 10.8% | 15.0% | 6.9% | 6.8% | -3.5% | 46.2% | -1.4% | -5.2% | -8.9% | -56.4% | -19.3% | -17.8% | |
| Pretax Margin | 15.0% | 19.0% | 7.8% | 7.1% | -4.1% | -2.3% | -5.6% | -9.6% | -2.7% | -74.4% | -17.4% | -16.6% | |
| EBITDA Margin | 15.2% | 20.3% | 10.8% | 12.0% | 1.4% | 3.7% | 0.28% | -1.9% | 5.6% | -63.3% | -7.1% | -12.4% | |
| ROA | 4.8% | 6.2% | 2.5% | 2.3% | -1.1% | 16.3% | -0.52% | -1.7% | -2.7% | -16.3% | -5.5% | -5.7% | |
| ROE | 5.8% | 7.7% | 3.4% | 3.1% | -1.5% | 21.1% | -0.77% | -2.6% | -4.2% | -24.4% | -8.8% | -9.3% | |
| ROIC | 4.9% | 6.7% | 2.8% | 3.1% | -1.6% | 18.2% | -0.81% | -2.2% | -1.7% | -22.0% | -5.1% | -6.5% |
Płynność i wypłacalność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.2 | 5.3 | 2.5 | 4.7 | 4.2 | 4.8 | 2.1 | 3.9 | 2.7 | 3.2 | 2.4 | 6.0 | |
| Quick Ratio | 2.9 | 2.6 | 1.2 | 2.0 | 1.8 | 2.2 | 0.9 | 1.6 | 2.0 | 2.3 | 1.7 | 4.6 | |
| Interest Coverage | · | · | 9.1 | 9.4 | -5.4 | -1.3 | -4.3 | -2.8 | -0.3 | -20.3 | -2.9 | -2.5 |
Efektywność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.4 | 0.4 | 0.3 | 0.3 | 0.4 | 0.4 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | |
| Inventory Turnover | 0.6 | 0.5 | 0.5 | 0.6 | 0.6 | 0.8 | 0.6 | 0.6 | 0.6 | 0.7 | 0.6 | 0.7 | |
| Receivables Turnover | 4.1 | 4.4 | 4.4 | 5.0 | 4.5 | 4.5 | 4.7 | 4.9 | 5.5 | 5.9 | 5.8 | 5.7 |
Na akcję
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $31.65 | $29.66 | $26.25 | $24.71 | $23.22 | $22.59 | $17.36 | $16.65 | $15.97 | $16.02 | $14.86 | $10.25 | |
| Revenue / Share | $16.32 | $14.51 | $12.63 | $11.09 | $10.10 | $9.71 | $9.52 | $8.41 | $7.53 | $6.72 | · | · | |
| Cash Flow / Share | $4.19 | $2.91 | $0.83 | $0.93 | $1.67 | $0.45 | $0.27 | $0.11 | $-0.05 | $-1.37 | · | · | |
| Cash / Share | $6.82 | $4.94 | $4.00 | $3.89 | $3.19 | $3.57 | $2.43 | $2.77 | $3.40 | $2.37 | $2.46 | $5.87 | |
| EPS (TTM) | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 | $4.50 | $-0.13 | $-0.44 | $-0.67 | $-3.81 | $-1.07 | $-0.92 |
Stopy Wzrostu
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 12.9% | 18.0% | 15.4% | 13.5% | -0.76% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 15.4% | 15.6% | 9.2% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 11.6% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -18.6% | 154.0% | 16.0% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 33.9% | · | -42.2% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -16.7% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -18.3% | 154.6% | 18.4% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 35.1% | · | -41.9% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -16.4% | · | · | · | · | · | · | · | · | · | · | · |
Wycena (TTM)
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B | $1.86B | $1.70B | $1.49B | $1.31B | $1.12B | $890M | $749M | |
| Net Income TTM | $349M | $427M | $168M | $142M | $-64M | $854M | $-24M | $-77M | $-117M | $-630M | $-172M | $-134M | |
| Market Cap | $11.43B | $12.54B | $18.18B | $19.28B | $16.25B | $15.94B | $15.21B | $15.18B | $15.68B | $14.30B | $16.92B | $13.48B | |
| P/E | 33.0 | 29.7 | 110.8 | 138.0 | -252.4 | 19.5 | -650.4 | -193.5 | -133.1 | -21.7 | -97.9 | -98.3 | |
| P/S | 3.5 | 4.4 | 7.5 | 9.2 | 8.8 | 8.6 | 8.9 | 10.2 | 11.9 | 12.8 | 19.0 | 18.0 | |
| P/B | 1.9 | 2.2 | 3.7 | 4.2 | 3.8 | 3.9 | 4.9 | 5.1 | 5.6 | 5.2 | 7.0 | 8.8 | |
| P / Tangible Book | 2.0 | 2.4 | 4.1 | 4.7 | 4.4 | 4.6 | · | · | · | · | · | · | |
| P / Cash Flow | 13.8 | 21.9 | 114.2 | 109.6 | 53.4 | 186.7 | 315.1 | 751.1 | -1790.6 | -62.8 | -76.3 | -183.3 | |
| P / FCF | 15.8 | 25.7 | 290.6 | 350.8 | 77.8 | -550.6 | -157.1 | -122.0 | -75.4 | -38.0 | -37.7 | -70.1 | |
| Earnings Yield | 3.0% | 3.4% | 0.90% | 0.72% | -0.40% | 5.1% | -0.15% | -0.52% | -0.75% | -4.6% | -1.0% | -1.0% |
Rachunek zysków i strat
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $990M | $766M | $875M | $776M | $825M | $745M | $747M | $746M | $712M | $649M | $646M | $581M | $595M | $596M | $538M | $505M | |
| Cost of Revenue | $203M | $195M | $276M | $140M | $150M | $152M | $136M | $188M | $130M | $125M | $138M | $128M | $131M | $135M | $147M | $116M | |
| R&D Expense | $207M | $179M | $192M | $409M | $161M | $159M | $174M | $185M | $184M | $205M | $206M | $191M | $177M | $172M | $173M | $158M | |
| SG&A Expense | $396M | $258M | $446M | $268M | $232M | $206M | $267M | $253M | $263M | $226M | $260M | $216M | $206M | $211M | $215M | $217M | |
| Operating Expenses | $879M | $637M | $919M | $823M | $549M | $521M | $586M | $632M | $592M | $560M | $619M | $551M | $530M | $534M | $551M | $508M | |
| Operating Income | $111M | $130M | $-45M | $-47M | $277M | $224M | $161M | $114M | $120M | $88M | $27M | $31M | $66M | $62M | $-13M | $-2M | |
| Interest Expense | $61M | $10M | · | · | $2M | $2M | · | · | · | $4M | · | $4M | $4M | $4M | · | $5M | |
| Interest Income | $10M | $23M | $19M | $18M | $19M | $19M | $18M | $18M | $20M | $19M | $18M | $16M | $13M | $12M | $9M | $5M | |
| Pretax Income | $61M | $141M | $-27M | $-26M | $298M | $238M | $170M | $134M | $132M | $106M | $19M | $42M | $71M | $57M | $-18M | $-2M | |
| Income Tax | $17M | $36M | $19M | $4M | $57M | $52M | $45M | $28M | $25M | $17M | $-1M | $1M | $15M | $6M | $-17M | $5M | |
| Net Income | $45M | $106M | $-47M | $-31M | $241M | $186M | $125M | $106M | $107M | $89M | $20M | $40M | $56M | $51M | $-249.0K | $-7M | |
| EPS (Basic) | $0.23 | $0.55 | $-0.24 | $-0.16 | $1.25 | $0.97 | $0.66 | $0.56 | $0.56 | $0.47 | $0.11 | $0.21 | $0.30 | $0.27 | $-0.01 | $-0.04 | |
| EPS (Diluted) | $0.23 | $0.54 | $-0.22 | $-0.16 | $1.23 | $0.95 | $0.65 | $0.55 | $0.55 | $0.46 | $0.10 | $0.21 | $0.29 | $0.27 | $0.01 | $-0.04 | |
| Shares (Basic) | 193,423,000 | 192,497,000 | · | 192,032,000 | 191,907,000 | 190,967,000 | · | 190,429,000 | 190,114,000 | 188,866,000 | · | 188,219,000 | 187,948,000 | 186,667,000 | · | 185,597,000 | |
| Shares (Diluted) | 194,467,000 | 197,671,000 | · | 192,032,000 | 197,091,000 | 196,474,000 | · | 197,147,000 | 200,505,000 | 199,262,000 | · | 191,173,000 | 194,998,000 | 194,363,000 | · | 185,597,000 | |
| EBITDA | $111M | $146M | · | $-47M | $277M | $246M | · | $114M | $120M | $116M | · | $26M | $59M | $86M | · | · |
Bilans
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $874M | $2.22B | $1.31B | $1.25B | $1.21B | $1.05B | $943M | $675M | $972M | $747M | · | $785M | $694M | $580M | · | $762M | |
| Receivables | $1.06B | $904M | $908M | $790M | $856M | $739M | $661M | $778M | $691M | $637M | · | $572M | $610M | $598M | · | $420M | |
| Inventory | $1.78B | $1.27B | $1.30B | $1.38B | $1.34B | $1.27B | $1.23B | $1.18B | $1.18B | $1.14B | · | $1.03B | $976M | $919M | · | $839M | |
| Other Current Assets | $254M | $206M | $186M | $204M | $177M | $182M | $202M | $169M | $160M | $163M | · | $225M | $193M | $173M | · | $150M | |
| Current Assets | $3.97B | $4.61B | $3.95B | $3.85B | $3.81B | $3.47B | $3.23B | $3.06B | $3.26B | $2.99B | · | $2.96B | $2.95B | $2.84B | · | $2.68B | |
| PP&E (Net) | $990M | $958M | $953M | $1.04B | $1.03B | $1.03B | $1.04B | $1.05B | $1.05B | $1.06B | · | $1.07B | $1.07B | $1.07B | · | $1.05B | |
| PP&E (Gross) | $2.10B | $2.05B | $2.03B | $1.99B | $1.96B | $1.94B | $1.93B | $1.91B | $1.96B | $1.95B | · | $1.92B | $1.90B | $1.88B | · | $1.83B | |
| Accum. Depreciation | $1.11B | $1.09B | $1.07B | $950M | $931M | $908M | $892M | $869M | $910M | $888M | · | $851M | $829M | $807M | · | $782M | |
| Goodwill | $656M | $196M | $196M | $196M | $196M | $196M | $196M | $196M | $196M | $196M | · | $196M | $196M | $196M | · | $196M | |
| Intangibles | $4.88B | $205M | $214M | $233M | $240M | $247M | $255M | $261M | $266M | $280M | · | $302M | $310M | $326M | · | $354M | |
| Other Non-current Assets | $338M | $276M | $277M | $271M | $249M | $236M | $251M | $199M | $191M | $185M | · | $165M | $144M | $150M | · | $152M | |
| Total Assets | $11.72B | $8.59B | $7.59B | $7.61B | $7.46B | $7.15B | $6.99B | $6.85B | $7.07B | $6.87B | · | $6.76B | $6.56B | $6.43B | · | $6.26B | |
| Accounts Payable | $1.01B | $793M | $759M | $798M | $684M | $628M | $607M | $716M | $572M | $594M | · | $670M | $597M | $598M | · | $493M | |
| Current Liabilities | $1.66B | $793M | $759M | $798M | $684M | $628M | $607M | $716M | $1.07B | $1.09B | · | $1.16B | $597M | $598M | · | $521M | |
| Capital Leases | · | · | $37M | · | · | · | $31M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $210M | $155M | $151M | $163M | $149M | $130M | $129M | $128M | $119M | $117M | · | $105M | $98M | $92M | · | $92M | |
| Total Liabilities | $5.40B | $2.38B | $1.51B | $1.56B | $1.43B | $1.35B | $1.33B | $1.44B | $1.78B | $1.80B | · | $1.86B | $1.78B | $1.77B | · | $1.70B | |
| Long-term Debt | $4.19B | $1.43B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Debt | $4.19B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $194.0K | $193.0K | $192.0K | $192.0K | $192.0K | $192.0K | $191.0K | $191.0K | $190.0K | $190.0K | · | $188.0K | $188.0K | $188.0K | · | $186.0K | |
| Retained Earnings | $304M | $260M | $154M | $201M | $232M | $-9M | $-195M | $-320M | $-426M | $-533M | · | $-642M | $-682M | $-738M | · | $-789M | |
| AOCI | $-9M | $-4M | $-13M | $-34M | $-45M | $19M | $62M | $5M | $27M | $-1M | · | $6M | $-19M | $-11M | · | $31M | |
| Stockholders' Equity | $6.32B | $6.21B | $6.09B | $6.06B | $6.03B | $5.79B | $5.66B | $5.41B | $5.29B | $5.07B | $4.95B | $4.90B | $4.78B | $4.66B | $4.60B | $4.57B | |
| Liabilities + Equity | $11.72B | $8.59B | $7.59B | $7.61B | $7.46B | $7.15B | $6.99B | $6.85B | $7.07B | $6.87B | · | $6.76B | $6.56B | $6.43B | · | $6.26B | |
| Shares Outstanding | 193,535,556 | 193,268,870 | 192,300,101 | 192,098,751 | 192,001,650 | 191,755,802 | 190,761,349 | 190,553,918 | 190,355,517 | 189,776,577 | 188,598,000 | 188,339,482 | 188,151,695 | 187,601,106 | 186,251,000 | 185,824,253 |
Przepływy pieniężne
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $98M | $16M | $20M | $18M | $19M | $22M | $24M | $19M | $26M | $27M | $27M | $26M | $25M | $26M | $25M | $25M | |
| Stock-based Comp | $76M | $43M | $47M | $49M | $48M | $38M | $52M | $43M | $48M | $58M | $55M | $48M | $50M | $54M | $47M | $55M | |
| Deferred Tax | $-7M | $9M | $613.0K | $-14M | $33M | $28M | $42M | $12M | $1M | $285.0K | $-25M | $-15M | $1M | $-6M | $-51M | $-4M | |
| Amort. of Intangibles | $73M | $4M | $5M | $5M | $5M | $5M | $10M | $5M | $14M | $14M | $15M | $16M | $16M | $16M | · | · | |
| Restructuring | $56M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | $46M | · | · | · | $-99M | · | · | · | $-128M | · | · | · | $-199M | · | · | |
| Operating Cash Flow | $168M | $221M | $100M | $369M | $185M | $174M | $186M | $221M | $119M | $47M | $27M | $136M | $70M | $-74M | $7M | $158M | |
| CapEx | $29M | $21M | $41M | $28M | $17M | $17M | $20M | $18M | $21M | $26M | $29M | $22M | $22M | $24M | $36M | $29M | |
| Investing Cash Flow | $-5.10B | $726M | $-42M | $-331M | $-13M | $-28M | $76M | $-16M | $90M | $-14M | $-65M | $-46M | $30M | $-30M | $-55M | $-23M | |
| Financing Cash Flow | $2.74B | $813M | $3M | $-2M | $-5M | $-39M | $3M | $-499M | $13M | $-43M | $11M | $-788.0K | $12M | $-41M | $11M | $8M | |
| Net Change in Cash | $-2.20B | $1.76B | $62M | $36M | $165M | $106M | $267M | $-297M | $225M | $-8M | $-30M | $91M | $114M | $-144M | $-37M | $142M | |
| Free Cash Flow | · | $200M | · | · | · | $158M | · | · | · | $21M | · | · | · | $-98M | · | · | |
| Levered FCF | · | $193M | · | · | · | · | · | · | · | $18M | · | · | · | $-102M | · | · |
Rentowność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 11.2% | 16.9% | · | -6.0% | 33.6% | 30.0% | · | 15.3% | 16.9% | 13.6% | · | 4.4% | 9.9% | 10.0% | · | · | |
| Net Margin | 4.5% | 13.8% | · | -4.0% | 29.1% | 24.9% | · | 14.2% | 15.0% | 13.7% | · | 7.0% | 9.4% | 8.5% | · | · | |
| Pretax Margin | 6.2% | 18.4% | · | -3.4% | 36.1% | 31.9% | · | 18.0% | 18.6% | 16.3% | · | 7.2% | 11.9% | 9.5% | · | · | |
| EBITDA Margin | 11.2% | 19.1% | · | -6.0% | 33.6% | 33.0% | · | 15.3% | 16.9% | 17.8% | · | 4.4% | 9.9% | 14.4% | · | · | |
| ROA | 0.47% | 1.3% | · | -0.43% | 3.3% | 2.6% | · | 1.6% | 1.6% | 1.3% | · | 0.62% | 0.88% | 0.81% | · | · | |
| ROE | 0.72% | 1.8% | · | -0.54% | 4.2% | 3.4% | · | 2.1% | 2.1% | 1.8% | · | 0.85% | 1.2% | 1.1% | · | · | |
| ROIC | 0.77% | 1.6% | · | -0.90% | 3.7% | 3.0% | · | 1.7% | 1.8% | 1.5% | · | 0.51% | 0.97% | 1.1% | · | · |
Płynność i wypłacalność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.4 | 5.8 | · | 4.8 | 5.6 | 5.5 | · | 4.3 | 3.1 | 2.7 | · | 2.5 | 4.9 | 4.8 | · | · | |
| Quick Ratio | 1.2 | 3.9 | · | 2.6 | 3.0 | 2.8 | · | 2.0 | 1.6 | 1.3 | · | 1.2 | 2.2 | 2.0 | · | · | |
| Debt / Equity | 0.7 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.6 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Interest Coverage | 1.8 | 13.5 | · | · | · | · | · | · | · | 24.9 | · | 6.8 | 15.7 | 16.0 | · | · |
Efektywność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | · | |
| Inventory Turnover | 0.1 | 0.2 | · | 0.1 | 0.1 | 0.1 | · | 0.2 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | · | |
| Receivables Turnover | 1.0 | 0.9 | · | 1.0 | 1.1 | 1.1 | · | 1.1 | 1.1 | 1.1 | · | 1.2 | 1.1 | 1.2 | · | · |
Na akcję
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $32.66 | $32.14 | · | $31.53 | $31.39 | $30.21 | · | $28.41 | $27.77 | $26.74 | · | $26.00 | $25.42 | $24.83 | · | · | |
| Revenue / Share | $5.09 | $3.88 | · | $4.04 | $4.19 | $3.79 | · | $3.78 | $3.55 | $3.26 | · | $3.04 | $3.05 | $3.07 | · | · | |
| Cash Flow / Share | · | $1.12 | · | · | · | $0.89 | · | · | · | $0.24 | · | · | · | $-0.38 | · | · | |
| Cash / Share | $4.52 | $11.50 | · | $6.51 | $6.32 | $5.47 | · | $3.54 | $5.11 | $3.94 | · | $4.17 | $3.69 | $3.09 | · | · | |
| EPS (TTM) | $0.39 | $1.39 | · | $2.67 | $3.38 | $2.70 | · | $1.66 | $1.32 | $1.06 | · | $0.78 | $0.53 | $0.39 | · | $0.43 |
Wycena (TTM)
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3.41B | $3.24B | · | $3.09B | $3.06B | $2.95B | · | $2.75B | $2.59B | $2.47B | · | $2.31B | $2.23B | $2.17B | · | $2.01B | |
| Net Income TTM | $73M | $269M | · | $520M | $657M | $524M | · | $322M | $257M | $205M | · | $147M | $100M | $72M | · | $84M | |
| Market Cap | $11.07B | $10.92B | · | $10.40B | $10.55B | $13.56B | · | $13.39B | $15.67B | $16.58B | · | $16.66B | $16.31B | $18.24B | · | · | |
| Enterprise Value | $14.39B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | 146.7 | 40.6 | · | 20.3 | 16.3 | 26.2 | · | 42.3 | 62.4 | 82.4 | · | 113.4 | 163.5 | 249.3 | · | 197.1 | |
| P/S | 3.3 | 3.4 | · | 3.4 | 3.4 | 4.6 | · | 4.9 | 6.1 | 6.7 | · | 7.2 | 7.3 | 8.4 | · | · | |
| P/B | 1.8 | 1.8 | · | 1.7 | 1.8 | 2.3 | · | 2.5 | 3.0 | 3.3 | · | 3.4 | 3.4 | 3.9 | · | · | |
| P / Tangible Book | 14.1 | 1.9 | · | 1.8 | 1.9 | 2.5 | · | 2.7 | 3.2 | 3.6 | · | 3.8 | 3.8 | 4.4 | · | 3.9 | |
| P / Cash Flow | · | 49.5 | · | · | · | 77.7 | · | · | · | 352.9 | · | · | · | -246.7 | · | · | |
| EV / Revenue | 4.2 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | 0.68% | 2.5% | · | 4.9% | 6.2% | 3.8% | · | 2.4% | 1.6% | 1.2% | · | 0.88% | 0.61% | 0.40% | · | 0.51% |
Najnowszy okres po lewej · wartości null pokazane jako ·
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Przychody | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B |
| Marża Operacyjna % | 12.7% | 17.0% | 6.5% | 7.1% | -4.5% |
| Zysk netto | $349M | $427M | $168M | $142M | $-64M |
| Rozwodniony EPS | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 |
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Wskaźnik bieżący | 5.2 | 5.3 | 2.5 | 4.7 | 4.2 |
| Wskaźnik Szybkości | 2.9 | 2.6 | 1.2 | 2.0 | 1.8 |
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $725M | $487M | $63M | $55M | $209M |
Właściciele instytucjonalni (13F) 617 emitentów · $12.2B łącznie · Na dzień 30 września 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 89 (-16 vs poprzedni kw.) | 75 (+10 vs poprzedni kw.) | 209 (+1 vs poprzedni kw.) | 198 (+29 vs poprzedni kw.) | +10.2M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| BlackRock, Inc. | $1 169 875 004 | 20 445 212 | 9,56% | Akcje |
| VANGUARD GROUP INC | $1 077 337 946 | 18 127 847 | 8,80% | Akcje |
| Dodge & Cox | $849 426 895 | 14 844 930 | 6,94% | Akcje |
| PRIMECAP MANAGEMENT CO/CA/ | $811 962 329 | 14 190 183 | 6,63% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $500 310 680 | 8 743 633 | 4,09% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $494 877 355 | 8 648 678 | 4,04% | Akcje |
| NORGES BANK | $469 659 128 | 8 207 954 | 3,84% | Akcje |
| STATE STREET CORP | $446 370 874 | 7 800 959 | 3,65% | Akcje |
| VIKING GLOBAL INVESTORS LP | $435 819 735 | 7 616 563 | 3,56% | Akcje |
| Vestal Point Capital, LP | $344 750 500 | 6 025 000 | 2,82% | Akcje |
| AQR CAPITAL MANAGEMENT LLC | $322 537 038 | 5 699 541 | 2,64% | Akcje |
| FMR LLC | $275 965 970 | 4 822 893 | 2,25% | Akcje |
| DIMENSIONAL FUND ADVISORS LP | $233 217 034 | 4 075 714 | 1,91% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $223 885 722 | 3 911 794 | 1,83% | Akcje |
| Capital Research Global Investors | $200 521 024 | 3 504 387 | 1,64% | Akcje |
| Deep Track Capital, LP | $189 254 063 | 3 307 481 | 1,55% | Akcje |
| MILLENNIUM MANAGEMENT LLC | $118 549 312 | 2 071 816 | 0,97% | Akcje |
| Assenagon Asset Management S.A. | $100 826 561 | 1 762 086 | 0,82% | Akcje |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $92 468 664 | 1 616 020 | 0,76% | Akcje |
| FIRST TRUST ADVISORS LP | $91 910 897 | 1 606 273 | 0,75% | Akcje |
| NORTHERN TRUST CORP | $89 154 711 | 1 558 104 | 0,73% | Akcje |
| MORGAN STANLEY | $86 115 553 | 1 504 989 | 0,70% | Akcje |
| Jones Hill Capital LP | $81 915 580 | 1 431 590 | 0,67% | Akcje |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $76 264 876 | 1 332 836 | 0,62% | Akcje |
| Swedbank AB | $75 232 112 | 1 314 787 | 0,61% | Akcje |
| UBS Group AG | $73 613 817 | 1 286 505 | 0,60% | Akcje |
| DNB Asset Management AS | $72 566 061 | 1 268 194 | 0,59% | Akcje |
| Caisse de depot et placement du Quebec | $70 749 440 | 1 236 446 | 0,58% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $70 030 356 | 1 223 879 | 0,57% | Akcje |
| GOLDMAN SACHS GROUP INC | $68 777 119 | 1 201 977 | 0,56% | Akcje |
| AMERIPRISE FINANCIAL INC | $66 255 506 | 1 157 865 | 0,54% | Akcje |
| Bank of New York Mellon Corp | $66 106 543 | 1 155 305 | 0,54% | Akcje |
| CITADEL ADVISORS LLC | $64 224 186 | 1 122 408 | 0,52% | Akcje |
| Balyasny Asset Management L.P. | $60 344 956 | 1 054 613 | 0,49% | Akcje |
| ARGA Investment Management, LP | $59 474 983 | 1 039 409 | 0,49% | Akcje |
| Brandywine Global Investment Management, LLC | $56 211 687 | 945 847 | 0,46% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $54 484 884 | 952 200 | 0,45% | Opcja kupna |
| FRANKLIN RESOURCES INC | $53 560 439 | 936 044 | 0,44% | Akcje |
| MACKENZIE FINANCIAL CORP | $53 321 258 | 931 864 | 0,44% | Akcje |
| JANUS HENDERSON GROUP PLC | $48 409 915 | 857 010 | 0,40% | Akcje |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $48 062 765 | 850 819 | 0,39% | Akcje |
| Hudson Bay Capital Management LP | $47 206 614 | 825 002 | 0,39% | Akcje |
| Russell Investments Group, Ltd. | $44 813 913 | 783 148 | 0,37% | Akcje |
| FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ | $40 949 264 | 715 646 | 0,33% | Akcje |
| LOOMIS SAYLES & CO L P | $40 835 454 | 713 657 | 0,33% | Akcje |
| JPMORGAN CHASE & CO | $40 573 267 | 694 550 | 0,33% | Akcje |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $39 869 980 | 696 784 | 0,33% | Akcje |
| Nuveen, LLC | $39 432 077 | 689 131 | 0,32% | Akcje |
| EDMOND DE ROTHSCHILD HOLDING S.A. | $39 311 857 | 687 030 | 0,32% | Akcje |
| Palo Alto Investors LP | $39 068 500 | 682 777 | 0,32% | Akcje |
Aktywiści i właściciele 5%+ 4 akcje
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| BioMarin Pharmaceutical Inc., BioMarin Falcons B.V., BioMarin Giants B.V. ×5 zgłoszenia | 2 lutego 2015 | · | Pierwotne zgłoszenie | · | SEC |
| Millenco LLC, Integrated Core Strategies (US) LLC, Catapult Partners, Ltd., Catapult Capital Management LLC, Millennium International Management LP, Millennium International Management GP LLC, Millennium Management LLC, Israel A. Englander ×2 zgłoszenia | 31 lipca 2009 | · | Pierwotne zgłoszenie | · | SEC |
| 6 czerwca 2005 | · | Pierwotne zgłoszenie | Kampania zarządu | SEC | |
| OrbiMed Advisors LLC, OrbiMed Capital LLC, Samuel D. Isaly, Richard B. Brewer, Joseph Klein, III ×2 zgłoszenia | 6 maja 2005 | · | Pierwotne zgłoszenie | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Insiderzy spółki 50 insiderów · 21 dyrektorzy generalni · 30 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Alexander Hardy | Chief Executive Officer | 17 marca 2026 F | 214 635 | 0 | 0 | $0 |
| Louis Drapeau | Chief Executive Officer | 2 maja 2005 A | 14 934 | 0 | 0 | $0 |
| Fredric D Price | Chief Executive Officer | 6 maja 2004 P | 79 285 | 0 | 0 | $0 |
| Brian Mueller | EVP, Chief Financial Officer | 17 marca 2026 F | 123 314 | 0 | 0 | $0 |
| Daniel K Spiegelman | EVP, Chief Financial Officer | 30 kwietnia 2019 A | 47 686 | 0 | 0 | $0 |
| Jeffrey H Cooper | SVP, Chief Financial Officer | 14 maja 2012 M | 41 089 | 0 | 0 | $0 |
| Henry J Fuchs | President, Worldwide R&D | 13 września 2024 F | 185 074 | 0 | 0 | $0 |
| Robert Baffi | President, Global Mfg/Tech Ops | 20 marca 2020 F | 117 138 | 0 | 0 | $0 |
| Gregory R Friberg | EVP, Chief R&D Officer | 30 września 2026 F | 47 732 | 0 | 2 | $-558 646 |
| George Eric Davis | EVP, Chief Legal Officer | 2 września 2026 S | 61 003 | 0 | 2 | $-2 762 781 |
| Cristin Hubbard | EVP, Chief Commercial Officer | 20 maja 2026 F | 42 472 | 0 | 0 | $0 |
| Charles Greg Guyer | EVP, Chief Technical Officer | 17 marca 2026 F | 84 140 | 0 | 1 | $-996 744 |
| Rashmi Virendra Ramchandani | VP, Chief Accounting Officer | 20 stycznia 2026 A | 25 610 | 0 | 0 | $0 |
| Erin Burkhart | GVP, Chief Accounting Officer | 20 maja 2025 S | 14 173 | 0 | 0 | $0 |
| Jeffrey Robert Ajer | EVP, Chief Commercial Officer | 2 maja 2024 S | 66 767 | 0 | 0 | $0 |
| Andrea Acosta | GVP, Chief Accounting Officer | 16 lipca 2021 F | 18 122 | 0 | 0 | $0 |
| Steve Aselage | EVP, Chief Business Officer | 2 lipca 2012 M | 59 030 | 0 | 0 | $0 |
| Emil D Kakkis | Chief Medical Officer | 2 marca 2009 M | 39 621 | 0 | 0 | $0 |
| Stuart J Swiedler | SVP, Clinical Affairs | 7 lipca 2008 A | 12 000 | 0 | 0 | $0 |
| Christopher M Starr | SVP, Chief Scientific Officer | 1 grudnia 2005 M | 295 176 | 0 | 0 | $0 |
| Jeffrey Landau | SVP, Administration | 31 października 2004 A | 2 740 | 0 | 0 | $0 |
| Robert M Plenge | Dyrektor | 10 września 2026 A | 6 140 | 0 | 0 | $0 |
| Elizabeth M Anderson | Dyrektor | 2 czerwca 2026 A | 41 940 | 0 | 0 | $0 |
| Barbara W. Bodem | Dyrektor | 2 czerwca 2026 A | 21 045 | 0 | 0 | $0 |
| Maykin Ho | Dyrektor | 2 czerwca 2026 A | 35 500 | 0 | 0 | $0 |
| Mark J Enyedy | Dyrektor | 2 czerwca 2026 A | 21 040 | 0 | 0 | $0 |
| Athena Countouriotis | Dyrektor | 2 czerwca 2026 A | 21 040 | 0 | 0 | $0 |
| Robert J. Hombach | Dyrektor | 2 czerwca 2026 A | 49 360 | 0 | 0 | $0 |
| Timothy P Walbert | Dyrektor | 2 czerwca 2026 A | 17 270 | 0 | 0 | $0 |
| Ian T Clark | Dyrektor | 2 czerwca 2026 A | 14 490 | 0 | 0 | $0 |
| Willard H Dere | Dyrektor | 2 czerwca 2026 A | 46 440 | 0 | 0 | $0 |
| Richard A Meier | Dyrektor | 20 maja 2025 A | 127 426 | 0 | 0 | $0 |
| Elaine J Heron | Dyrektor | 3 czerwca 2024 M | 97 720 | 0 | 0 | $0 |
| David E I Pyott | Dyrektor | 21 maja 2024 A | 49 750 | 0 | 0 | $0 |
| Jean Jacques Bienaime | Dyrektor | 20 maja 2024 F | 473 792 | 0 | 0 | $0 |
| Dennis Slamon | Dyrektor | 18 marca 2024 M | 31 299 | 0 | 0 | $0 |
| Mark J Alles | Dyrektor | 23 maja 2023 A | 15 095 | 0 | 0 | $0 |
| Bryan V Lawlis | Dyrektor | 23 maja 2023 A | 33 140 | 0 | 0 | $0 |
| Michael G Grey | Dyrektor | 5 marca 2021 M | 42 840 | 0 | 0 | $0 |
| Alan Lewis | Dyrektor | 4 czerwca 2019 A | 25 590 | 0 | 0 | $0 |
| Kathryn E Falberg | Dyrektor | 15 lipca 2016 A | 2 640 | 0 | 0 | $0 |
| William D Young | Dyrektor | 10 czerwca 2015 A | 11 875 | 0 | 0 | $0 |
| Kenneth Bate | Dyrektor | 10 czerwca 2015 A | 11 875 | 0 | 0 | $0 |
| Pierre Lapalme | Dyrektor | 10 czerwca 2015 A | 31 250 | 0 | 0 | $0 |
| Joseph Klein III | Dyrektor | 8 marca 2010 S | 35 000 | 0 | 0 | $0 |
| Franz L Cristiani | Dyrektor | 14 czerwca 2006 A | · | 0 | 0 | $0 |
| Erich Sager | Dyrektor | 24 lutego 2006 M | 3 309 | 0 | 0 | $0 |
| Gwynn Williams | Dyrektor | 30 listopada 2004 A | 812 565 | 0 | 0 | $0 |
| John Urquhart | Dyrektor | 28 lipca 2004 A | · | 0 | 0 | $0 |
| Mark Wood | · | 22 maja 2013 M | 20 277 | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Posiadanie ETF-ów Posiadane przez 81 funduszy ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| PBE · Invesco Exchange-Traded Fund Trust | 2,51% | 177 471 SH | 1 października 2026 | Dziennie |
| BBP · ETFis Series Trust I | 1,48% | 24 255 NS | 31 lipca 2026 | N-PORT |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,31% | 15 080 NS | 31 lipca 2026 | N-PORT |
| SRHQ · Elevation Series Trust | 1,17% | 41 384 NS | 31 lipca 2026 | N-PORT |
| RNIN · EA Series Trust | 1,15% | 35 050 NS | 31 lipca 2026 | N-PORT |
| IBB · iShares Trust | 0,92% | 1 454 497 SH | 11 września 2026 | Dziennie |
| CALF · Pacer Funds Trust | 0,79% | 482 285 NS | 31 lipca 2026 | N-PORT |
| JOET · Virtus ETF Trust II | 0,76% | 30 936 NS | 31 lipca 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,76% | 13 701 SH | 1 października 2026 | Dziennie |
| LABU · Direxion Shares ETF Trust | 0,73% | 60 076 NS | 31 lipca 2026 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 0,44% | 77 415 NS | 31 lipca 2026 | N-PORT |
| IQSM · New York Life Investments ETF Trust | 0,44% | 24 133 NS | 31 lipca 2026 | N-PORT |
| QVMM · Invesco Exchange-Traded Fund Trust … | 0,38% | 26 065 SH | 1 października 2026 | Dziennie |
| IVOG · VANGUARD ADMIRAL FUNDS | 0,33% | 108 709 SH | 19 sierpnia 2026 | Dziennie |
| PTMC · Pacer Funds Trust | 0,33% | 21 272 NS | 31 lipca 2026 | N-PORT |
| DFSV · Dimensional ETF Trust | 0,32% | 436 803 NS | 31 lipca 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,30% | 2 559 860 SH | 19 sierpnia 2026 | Dziennie |
| IVOO · VANGUARD ADMIRAL FUNDS | 0,30% | 312 378 SH | 19 sierpnia 2026 | Dziennie |
| BKMC · BNY Mellon ETF Trust | 0,28% | 29 895 NS | 31 lipca 2026 | N-PORT |
| IVOV · VANGUARD ADMIRAL FUNDS | 0,27% | 71 381 SH | 19 sierpnia 2026 | Dziennie |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0,25% | 84 704 NS | 31 lipca 2026 | N-PORT |
| MIDU · Direxion Shares ETF Trust | 0,25% | 2 838 NS | 31 lipca 2026 | N-PORT |
| PWS · Pacer Funds Trust | 0,20% | 821 NS | 31 lipca 2026 | N-PORT |
| IYH · iShares Trust | 0,20% | 111 984 SH | 11 września 2026 | Dziennie |
| SMMD · iShares Trust | 0,17% | 102 244 SH | 11 września 2026 | Dziennie |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,17% | 16 041 NS | 31 lipca 2026 | N-PORT |
| VFMF · VANGUARD WELLINGTON FUND | 0,16% | 19 998 SH | 19 sierpnia 2026 | Dziennie |
| DFAS · Dimensional ETF Trust | 0,16% | 401 829 NS | 31 lipca 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,15% | 84 531 NS | 31 lipca 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,15% | 534 462 SH | 19 sierpnia 2026 | Dziennie |
| ISCG · iShares Trust | 0,15% | 21 366 SH | 11 września 2026 | Dziennie |
| VFVA · VANGUARD WELLINGTON FUND | 0,14% | 20 990 SH | 19 sierpnia 2026 | Dziennie |
| RWK · Invesco Exchange-Traded Fund Trust … | 0,13% | 28 086 SH | 1 października 2026 | Dziennie |
| ESML · iShares Trust | 0,13% | 56 252 SH | 11 września 2026 | Dziennie |
| VB · VANGUARD INDEX FUNDS | 0,13% | 4 433 137 SH | 19 sierpnia 2026 | Dziennie |
| IWS · iShares Trust | 0,12% | 286 469 SH | 11 września 2026 | Dziennie |
| VXF · VANGUARD INDEX FUNDS | 0,12% | 2 217 617 SH | 19 sierpnia 2026 | Dziennie |
| WSML · iShares Trust | 0,11% | 11 104 SH | 11 września 2026 | Dziennie |
| FYEE · Fidelity Greenwood Street Trust | 0,11% | 3 901 NS | 31 lipca 2026 | N-PORT |
| PEXL · Pacer Funds Trust | 0,09% | 797 NS | 31 lipca 2026 | N-PORT |
| IWR · iShares Trust | 0,09% | 787 222 SH | 11 września 2026 | Dziennie |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0,09% | 11 519 SH | 1 października 2026 | Dziennie |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,08% | 18 000 NS | 31 lipca 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0,06% | 5 934 NS | 31 lipca 2026 | N-PORT |
| DFAT · Dimensional ETF Trust | 0,06% | 143 957 NS | 31 lipca 2026 | N-PORT |
| FBUF · Fidelity Greenwood Street Trust | 0,05% | 212 NS | 31 lipca 2026 | N-PORT |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0,05% | 41 047 SH | 1 października 2026 | Dziennie |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,05% | 4 814 NS | 31 lipca 2026 | N-PORT |
| DFSU · Dimensional ETF Trust | 0,05% | 18 819 NS | 31 lipca 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,04% | 347 063 NS | 31 lipca 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,03% | 19 135 NS | 31 lipca 2026 | N-PORT |
| IWD · iShares Trust | 0,03% | 425 477 SH | 11 września 2026 | Dziennie |
| DSI · iShares Trust | 0,03% | 27 701 SH | 11 września 2026 | Dziennie |
| REVS · Columbia ETF Trust I | 0,03% | 1 740 NS | 31 lipca 2026 | N-PORT |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0,03% | 115 700 SH | 19 sierpnia 2026 | Dziennie |
| DFUV · Dimensional ETF Trust | 0,03% | 74 321 NS | 31 lipca 2026 | N-PORT |
| PRF · Invesco Exchange-Traded Fund Trust | 0,03% | 45 172 SH | 1 października 2026 | Dziennie |
| TILT · FlexShares Trust | 0,03% | 9 322 NS | 31 lipca 2026 | N-PORT |
| FHEQ · Fidelity Greenwood Street Trust | 0,02% | 3 375 NS | 31 lipca 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,02% | 44 514 NS | 31 lipca 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,02% | 6 143 206 SH | 19 sierpnia 2026 | Dziennie |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0,02% | 31 861 SH | 19 sierpnia 2026 | Dziennie |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,02% | 16 031 SH | 19 sierpnia 2026 | Dziennie |
| ESGV · VANGUARD WORLD FUND | 0,02% | 43 345 SH | 19 sierpnia 2026 | Dziennie |
| IUSG · iShares Trust | 0,02% | 97 914 SH | 11 września 2026 | Dziennie |
| IWB · iShares Trust | 0,02% | 130 403 SH | 11 września 2026 | Dziennie |
| IYY · iShares Trust | 0,02% | 8 059 SH | 11 września 2026 | Dziennie |
| ITOT · iShares Trust | 0,02% | 253 576 SH | 11 września 2026 | Dziennie |
| IUSV · iShares Trust | 0,02% | 71 403 SH | 11 września 2026 | Dziennie |
| RECS · Columbia ETF Trust I | 0,02% | 16 398 NS | 31 lipca 2026 | N-PORT |
| IWV · iShares Trust | 0,02% | 51 240 SH | 11 września 2026 | Dziennie |
| DFUS · Dimensional ETF Trust | 0,02% | 53 858 NS | 31 lipca 2026 | N-PORT |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,01% | 169 270 SH | 19 sierpnia 2026 | Dziennie |
| DFLV · Dimensional ETF Trust | 0,00% | 1 028 NS | 31 lipca 2026 | N-PORT |
| IJH · iShares Trust | · | 6 782 201 SH | 11 września 2026 | Dziennie |
| IJK · iShares Trust | · | 638 802 SH | 11 września 2026 | Dziennie |
| IJJ · iShares Trust | · | 423 789 SH | 21 sierpnia 2026 | Dziennie |
| XJH · iShares Trust | · | 26 404 SH | 8 września 2026 | Dziennie |
| ISCB · iShares Trust | · | 8 699 SH | 11 września 2026 | Dziennie |
| ISCV · iShares Trust | · | 27 848 SH | 11 września 2026 | Dziennie |
| SMMV · iShares Trust | · | 29 688 SH | 19 sierpnia 2026 | Dziennie |
BMRN Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
12-miesięczny cel cenowy
26 analityków · 2026-10-02Średnia cel $91.62 +60,2%
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
Podstawa R/R, ceny według zamknięcia z ostatniego końca roku obrotowego każdej spółki.
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| BMRN | $11.43B | 33.0 | 12.9% | 10.8% | 5.8% | · |
| BBIO | $14.90B | -20.2 | 126.3% | -146.0% | 41.2% | · |
| TWST | $1.71B | -21.6 | 20.3% | -20.6% | -17.0% | · |
| HALO | $7.93B | 26.3 | 37.5% | 22.7% | 166.1% | · |
| MDGL | $13.30B | -45.3 | 432.1% | -30.1% | -44.4% | · |
| IBRX | $2.00B | -5.2 | 668.3% | -310.2% | 71.0% | · |
| KRYS | $7.20B | 36.0 | 33.9% | 52.6% | 18.1% | · |
| KYMR | $6.33B | -21.1 | -16.7% | -794.0% | -24.4% | · |
| CYTK | $7.81B | -9.7 | 376.6% | -891.6% | 152.7% | · |
Najnowsze wiadomości Najnowsze nagłówki wspominające o tej firmie
Sygnały transakcyjne Ostatnie sygnały kupna/sprzedaży z ceną wejścia i wskaźnikiem ryzyka/zysku
Obecnie brak otwartego sygnału — żadna karta nie jest wypełniona, i to jest uczciwe.
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
Wybierz wskaźniki, które są dla Ciebie ważne — kliknij + obok dowolnego wiersza w sekcji Pełne dane fundamentalne powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.